Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab

被引：0
|
作者：
Claus-Henning Köhne
Meinolf Karthaus
Laurent Mineur
Josef Thaler
Marc Van den Eynde
Javier Gallego
Reija Koukakis
Marloes Berkhout
Ralf-Dieter Hofheinz
机构：
[1] Klinikum Oldenburg,Department of Oncology and Haematology
[2] Städtisches Klinikum München,Department of Hematology and Oncology
[3] Institut Sainte Catherine,Département de Cancérologie Digestive
[4] Klinikum Wels-Grieskirchen,Internal Medicine IV (Hematology and Medical Oncology)
[5] Cliniques Universitaires Saint-Luc UCL,Department of Gastroenterology and Medical Oncology, Institut Roi Albert II
[6] Hospital General Universitario de Elche,Servicio de Oncología Médica
[7] Amgen Ltd,Department of Biostatistics
[8] Amgen B.V.,Medical Development
[9] Tagestherapiezentrum,undefined
[10] Interdisziplinäres Tumorzentrum,undefined
[11] Universitätsmedizin Mannheim,undefined
来源：
Drugs in R&D | 2019年 / 19卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：267 / 275
页数：8
相关论文
共 50 条
  • [1] Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab
    Koehne, Claus-Henning
    Karthaus, Meinolf
    Mineur, Laurent
    Thaler, Josef
    Van den Eynde, Marc
    Gallego, Javier
    Koukakis, Reija
    Berkhout, Marloes
    Hofheinz, Ralf-Dieter
    DRUGS IN R&D, 2019, 19 (03) : 267 - 275
  • [2] Impact of tumour RAS/BRAF status in a first-line study of panitumumab plus FOLFIRI in patients with metastatic colorectal cancer
    Karthaus, Meinolf
    Hofheinz, Ralf-Dieter
    Mineur, Laurent
    Letocha, Henry
    Greil, Richard
    Thaler, Josef
    Fernebro, Eva
    Oliner, Kelly S.
    Boedigheimer, Michael
    Twomey, Brian
    Zhang, Ying
    Demonty, Gaston
    Koehne, Claus-Henning
    BRITISH JOURNAL OF CANCER, 2016, 115 (10) : 1215 - 1222
  • [3] Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer
    Douillard, Jean-Yves
    Siena, Salvatore
    Peeters, Marc
    Koukakis, Reija
    Terwey, Jan-Henrik
    Tabernero, Josep
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (10) : 1231 - 1242
  • [4] Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer
    Meinolf Karthaus
    Ralf-Dieter Hofheinz
    Laurent Mineur
    Henry Letocha
    Richard Greil
    Josef Thaler
    Eva Fernebro
    Kelly S Oliner
    Michael Boedigheimer
    Brian Twomey
    Ying Zhang
    Gaston Demonty
    Claus-Henning Köhne
    British Journal of Cancer, 2016, 115 : 1215 - 1222
  • [5] Impact of primary tumour location (PTL) on outcomes in patients (pts) with metastatic colorectal cancer (mCRC) undergoing first-line panitumumab (Pmab) plus FOLFIRI treatment
    Karthaus, Meinolf
    Van Den Eynde, Marc
    Mineur, Laurent
    Thaler, Josef
    Koukakis, Reija
    Berkhout, Marloes
    Gallego, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [6] Assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer
    Kr, A.
    P, S. S.
    Kumar, R. C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [7] Retrospective analysis of quality of life and early tumour shrinkage during first-line FOLFOX4 ± panitumumab in RAS wild-type metastatic colorectal carcinoma
    Siena, S.
    Tabernero, J.
    Bodoky, G.
    Cunningham, D.
    Rivera, F.
    Ruff, P.
    Canon, J. -L.
    Koukakis, R.
    Demonty, G.
    Douillard, J. -Y.
    ANNALS OF ONCOLOGY, 2016, 27 : 110 - 111
  • [8] Primary tumour location and efficacy of first-line anti-EGFR agents in the treatment of RAS wild-type metastatic colorectal cancer
    Marinho, J.
    Leao, I.
    Neto, E.
    Guedes, H.
    Costa, T.
    Capela, A.
    Moreira Pinto, A.
    Custodio, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S168 - S169
  • [9] Tumour response outcomes during the first-line treatment of metastatic colorectal carcinoma (mCRC) with panitumumab plus FOLFIRI
    Karthaus, M.
    Hofheinz, R.
    Mineur, L.
    Letocha, H.
    Greil, R.
    Thaler, J.
    Fernebro, E.
    Zhang, Y.
    Oliner, K. S.
    Demonty, G.
    Koehne, C. H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S375 - S376
  • [10] Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab
    Tamotsu Sagawa
    Yasushi Sato
    Masahiro Hirakawa
    Kyoko Hamaguchi
    Akira Fukuya
    Koichi Okamoto
    Hiroshi Miyamoto
    Naoki Muguruma
    Koshi Fujikawa
    Yasuo Takahashi
    Tetsuji Takayama
    Scientific Reports, 10
12345